Sugi Predict

Sugi Predict / Compounds / SCHEMBL15920709

SCHEMBL15920709

SCHEMBL15920709

C#C[C@@H]1CN(C(=O)OC(C)(C)C)CCO1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ RECQL P46063 1/20 0.49
▸ MAPT P10636 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ HPGD P15428 1/20 0.41
▸ NR1H2 P55055 1/20 0.39
▸ EPHX1 P07099 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ PTPN2 P17706 1/20 0.36
▸ PTPN1 P18031 1/20 0.36
▸ PTPN6 P29350 1/20 0.36
▸ USP30 Q70CQ3 3/20 0.36
▸ EPHX2 P34913 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15920689 1.00 USP2 (0.51) USP2SMN1; SMN2RECQLMAPTALDH1A1
SCHEMBL15920687 1.00 USP2 (0.51) USP2SMN1; SMN2RECQLMAPTALDH1A1
SCHEMBL23754562 0.92 MEN1 (0.51) USP2SMN1; SMN2RECQLMAPTALDH1A1
SCHEMBL29753767 0.87 RECQL (0.58) USP2SMN1; SMN2RECQLMAPTALDH1A1
SCHEMBL4202170 0.87 USP2 (0.53) USP2SMN1; SMN2RECQLMAPTALDH1A1
SCHEMBL28619043 0.83 PDK1 (0.39) USP2RECQLALDH1A1MEN1KMT2A
SCHEMBL22168147 0.83 PDK1 (0.39) USP2RECQLALDH1A1MEN1KMT2A
SCHEMBL25177445 0.83 USP2 (0.49) USP2SMN1; SMN2RECQLMAPTALDH1A1
SCHEMBL25630739 0.80 USP2 (0.46) USP2SMN1; SMN2RECQLMAPTALDH1A1
SCHEMBL22168078 0.79 USP2 (0.48) USP2SMN1; SMN2RECQLMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026087613-A1 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS, PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2026-04-30 — — WO disclosed
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-12528785-B2 MDM2 degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-01-20 — — US disclosed
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-12258341-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2025-03-25 — — US disclosed
US-20240424110-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-12-26 — — US disclosed
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-11932624-B2 MDM2 degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-03-19 — — US disclosed
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 — — US disclosed
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 — — US disclosed
US-20170143730-A1 Imidazopyridine Compounds and Uses Thereof GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2017-05-25 — — US disclosed
US-20170143730-A1 Imidazopyridine Compounds and Uses Thereof GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2017-05-25 — — US disclosed
US-20170143730-A1 Imidazopyridine Compounds and Uses Thereof GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2017-05-25 — — US disclosed
US-9598409-B2 Imidazopyridine compounds and uses thereof NEOMED INSTITUTE (CA) 2017-03-21 — — US disclosed
US-9598409-B2 Imidazopyridine compounds and uses thereof NEOMED INSTITUTE (CA) 2017-03-21 — — US disclosed
US-9598409-B2 Imidazopyridine compounds and uses thereof NEOMED INSTITUTE (CA) 2017-03-21 — — US disclosed
US-20150361078-A1 Imidazopyridine Compounds and Uses Thereof GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2015-12-17 — — US disclosed
US-20150361078-A1 Imidazopyridine Compounds and Uses Thereof GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2015-12-17 — — US disclosed
EP-2951177-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF Neomed Institute (CA) 2015-12-09 — — EP disclosed
WO-2014117274-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF NEOMED INSTITUTE (CA) 2014-08-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258341-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 USP2 141/4885SMN1; SMN2 2647/4885RECQL 2866/4885
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF MDM2, TP53, MDM4 USP2 32/4885SMN1; SMN2 3149/4885RECQL 666/4885
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 USP2 141/4885SMN1; SMN2 2647/4885RECQL 2866/4885
US-20240424110-A1 MDM2 DEGRADERS AND USES THEREOF MDM2, USP2, MYCBP2 USP2 2/4885SMN1; SMN2 2413/4885RECQL 1769/4885
US-12528785-B2 MDM2 degraders and uses thereof MDM2, ADRM1, RBX1 USP2 34/4885SMN1; SMN2 737/4885RECQL 553/4885
US-20150361078-A1 Imidazopyridine Compounds and Uses Thereof NISCH, ABL1, PAICS USP2 4058/4885SMN1; SMN2 1459/4885RECQL 2005/4885
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 USP2 141/4885SMN1; SMN2 2647/4885RECQL 2866/4885
US-11932624-B2 MDM2 degraders and uses thereof MDM2, TP53, MDM4 USP2 32/4885SMN1; SMN2 3149/4885RECQL 666/4885
US-20170143730-A1 Imidazopyridine Compounds and Uses Thereof NISCH, ABL1, PAICS USP2 4058/4885SMN1; SMN2 1459/4885RECQL 2005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.